Brain Cancer Clinical Trials in Cleveland

Showing 41-60 of 100 trials

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

NCT01894061

NovoTTF-100A is a device and Bevacizumab is a study drug that have both been approved by the FDA (Food and Drug Administration) for use as monotherapy in treating glioblastoma multiforme. The NovoTTF-l00A is a portable battery operated device which produces TTFields within the human body using surface electrodes (transducer arrays). Intermediate frequency electric fields (TTFields) stunt the growth of tumor cells. The purpose of this study is to determine the efficacy of the combination of Bevacizumab and NovoTTF-100A in Bevacizumab naive (meaning have never received bevacizumab before) patients with recurrent glioblastoma (GBM) as measured by 6-month progression free survival.

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

Case Comprehensive Cancer Center25 participantsStarted Sep 2013

Cincinnati, Ohio, United States • Cleveland, Ohio, United States • Cleveland, Ohio, United States

COMPLETEDPHASE1< 1 mile

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905

This pilot phase I clinical trial studies how well lapatinib ditosylate before surgery works in treating patients with high-grade glioma that has come back after a period of time during which the tumor could not be detected. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Anaplastic AstrocytomaAnaplastic EpendymomaAnaplastic Oligodendroglioma+4 more

National Cancer Institute (NCI)29 participantsStarted Nov 2016

Los Angeles, California, United States • Baltimore, Maryland, United States • Boston, Massachusetts, United States +9 more locations

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Brain Cancer Trials in Other Cities

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

BG & TMZ Therapy of Glioblastoma Multiforme

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Expanded Access Protocol Using 131I-MIBG

Glioma Supra Marginal Incision Trial

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Other Conditions in Cleveland